Revenue Performance - Total revenues decreased by 91% to $966,000 for the three months ended September 30, 2025, compared to $10.5 million in the same period the prior year[90] - Product sales, net decreased by 12% to $582,000 for the three months ended September 30, 2025, primarily due to the automatic termination of the ANI CSA in Q2 2025[91] - License and collaboration agreement revenue decreased by 98% to $150,000 for the three months ended September 30, 2025, driven by the recognition of remaining deferred revenue related to the 2023 agreement for YUTIQ® product rights[92] - Total revenues for the nine months ended September 30, 2025, were $30.8 million, a decrease of $934,000 or 3% compared to the same period in 2024[101] - Product sales, net decreased by $1.1 million, or 46%, to $1.3 million for the nine months ended September 30, 2025, primarily due to the automatic termination of the ANI CSA[102] - Royalty income increased by $11.5 million, or 830%, to $12.9 million for the nine months ended September 30, 2025, mainly due to the recognition of deferred SWK royalty revenue[104] Expenses and Losses - Research and development expenses increased by 62% to $47.8 million for the three months ended September 30, 2025, compared to $29.5 million in the same period the prior year[90] - Total operating expenses increased by 46% to $63.0 million for the three months ended September 30, 2025, compared to $43.3 million in the same period the prior year[90] - Net loss increased by 103% to $59.7 million for the three months ended September 30, 2025, compared to a net loss of $29.4 million in the same period the prior year[90] - Net loss per share increased by 57% to $(0.85) for the three months ended September 30, 2025, compared to $(0.54) in the same period the prior year[90] - For the nine months ended September 30, 2025, the net loss was $164.4 million, an increase of $74.9 million compared to a net loss of $89.5 million for the same period in 2024[118] - Operating cash outflows for the nine months ended September 30, 2025 totaled $175.1 million, compared to $90.4 million for the same period in 2024, reflecting an increase of $84.7 million[119] Research and Development - DURAVYU™ is currently being evaluated in Phase 3 pivotal trials for wet AMD, with data readout expected to begin in mid-2026[85] - The first patient dosing for pivotal Phase 3 trials evaluating DURAVYU™ for DME is anticipated in Q1 2026[89] - Research and development expenses increased by $72.3 million, or 81%, to $161.8 million for the nine months ended September 30, 2025, attributed to ongoing DURAVYU™ Phase 3 clinical trials[106] Cash and Financing - The company has cash, cash equivalents, and investments totaling $204.0 million as of September 30, 2025, which, along with net proceeds of approximately $162.1 million from an equity financing, will fund operations into Q4 2027[80] - Cash, cash equivalents, and investments in marketable securities totaled $204.0 million as of September 30, 2025, expected to fund operations into the fourth quarter of 2027[115] - Net cash provided by investing activities for the nine months ended September 30, 2025 was $145.5 million, a significant increase of $266.6 million compared to a net cash outflow of $119.7 million in 2024[120] - Net cash provided by financing activities for the nine months ended September 30, 2025 totaled $6.7 million, a decrease of $5.6 million from $12.3 million in 2024[121] - The company issued 495,118 shares of Common Stock in 2025, raising $6.7 million through its ATM program[121] Operational Challenges - The company anticipates continued substantial operating losses for at least the next several years as it develops product candidates and seeks marketing approval[117] - Cash outflows related to changes in working capital for the nine months ended September 30, 2025 were $29.5 million, including $28.6 million of deferred revenue related to licensing agreements[118] - The company reported cash outflows of $29.5 million in working capital adjustments, reflecting ongoing operational challenges[118] - General and administrative expenses increased by $1.5 million, or 12%, to $14.5 million for the three months ended September 30, 2025, mainly due to an increase in contingent liability[98] - Interest income decreased by $1.1 million, or 32%, to $2.3 million for the three months ended September 30, 2025, driven by lower cash available for investment[99] - Non-cash expenses for the nine months ended September 30, 2025 included $21.1 million of stock-based compensation, compared to $28.8 million in 2024[119] - The company incurred $2.3 million for the purchase of property and equipment in 2025, compared to $3.7 million in 2024[120] - Deferred revenue related to the licensing of YUTIQ® product rights to ANI was $22.1 million in 2024, indicating a consistent revenue stream from licensing agreements[119]

Financial Performance - Intellia ended Q3 2025 with approximately $670 million in cash, cash equivalents, and marketable securities, expected to fund operations into mid-2027[3] - Collaboration revenue for Q3 2025 was $13.8 million, up from $9.1 million in Q3 2024, reflecting a $4.7 million increase primarily from cost reimbursements with Regeneron Pharmaceuticals[12] - R&D expenses decreased to $94.7 million in Q3 2025 from $123.4 million in Q3 2024, a reduction of $28.7 million driven by lower employee-related expenses and research materials[12] - Net loss for Q3 2025 was $101.3 million, compared to a net loss of $135.7 million in Q3 2024[12] - Net loss for Q3 2025 was $101,324,000, compared to a net loss of $135,712,000 in Q3 2024, showing an improvement of 25.3%[19] - Net loss per share for Q3 2025 was $0.92, down from $1.34 in Q3 2024[19] - Interest income for Q3 2025 was $6,714,000, down from $12,122,000 in Q3 2024[19] - Change in fair value of investments for Q3 2025 was $3,439,000, compared to a loss of $3,064,000 in Q3 2024[19] Operational Updates - Enrollment in the MAGNITUDE Phase 3 trial for ATTR-CM includes over 650 patients, while MAGNITUDE-2 has 47 patients enrolled for ATTRv-PN[6] - The FDA placed a clinical hold on the MAGNITUDE and MAGNITUDE-2 trials for nex-z, with the company awaiting further guidance[5] - Topline data from the HAELO Phase 3 trial of lonvo-z is expected by mid-2026, with a potential U.S. commercial launch in the first half of 2027[3] - The company plans to present longer-term data from the Phase 1/2 trial of lonvo-z on November 8, 2025[12] - Intellia has suspended milestone guidance for nex-z pending regulatory alignment due to the clinical hold[7] Expense Management - Stock-based compensation included in R&D expenses was $12.2 million for Q3 2025[12] - Total operating expenses decreased to $125,259,000 in Q3 2025 from $153,881,000 in Q3 2024, representing a reduction of 18.7%[19] Balance Sheet Highlights - Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $669,858,000, a decrease from $861,730,000 as of December 31, 2024[20] - Total assets decreased to $925,275,000 as of September 30, 2025, from $1,191,015,000 as of December 31, 2024[20] - Total liabilities decreased significantly to $176,853,000 as of September 30, 2025, from $319,059,000 as of December 31, 2024[20] - Total stockholders' equity decreased to $748,422,000 as of September 30, 2025, from $871,956,000 as of December 31, 2024[20]

Financial Performance - For Q3 2025, B. Riley Securities reported total revenue of approximately $109.1 million and adjusted net revenue of approximately $75.7 million[3] - Net income for the third quarter was approximately $41.8 million, while adjusted net income totaled approximately $18.9 million[3] - Investment banking revenue was $53.9 million, while institutional brokerage revenue was $51.6 million for the quarter[14] Capital Management - The company raised approximately $10.5 billion in capital for clients through equity and debt financings during the quarter[2] - B. Riley Securities has a debt-free balance sheet with cash and securities totaling $145.9 million as of September 30, 2025[10] - The Board approved a dividend of $0.40 per common share, amounting to approximately $7.4 million in total distribution[10] - The company continues to evaluate future returns of capital to shareholders based on available excess capital and business growth prospects[10] Risk Management and Strategy - The company emphasized a disciplined approach to risk management and recruiting new talent to strengthen its platform[2] - Upcoming conferences, including the Convergence Conference focusing on AI and blockchain, reflect the company's commitment to high-quality engagement[2] Adjusted Financial Metrics - Adjusted net income excludes certain non-GAAP adjustments, providing a clearer view of the firm's operating performance[4]

Exhibit 99.1 www.brileysecurities.com B. Riley Securities Releases Third Quarter 2025 Business Update and Financial Highlights ARLINGTON, VA, November 6, 2025 – B. Riley Securities Holdings, Inc. ("B. Riley Securities," "BRS" or the "Company"), a leading middle market investment bank, today provided a business update and certain preliminary financial results for the three-month period ended September 30, 2025. Financial Highlights Management Commentary "B. Riley Securities delivered a highly profitable thir ...

Exhibit 99.1 www.brileysecurities.com B. Riley Securities Releases Third Quarter 2025 Business Update and Financial Highlights ARLINGTON, VA, November 6, 2025 – B. Riley Securities Holdings, Inc. ("B. Riley Securities," "BRS" or the "Company"), a leading middle market investment bank, today provided a business update and certain preliminary financial results for the three-month period ended September 30, 2025. Financial Highlights Management Commentary "B. Riley Securities delivered a highly profitable thir ...

Financial Performance - Revenue for the three months ended September 30, 2025, was $181,573,000, a 1% increase from $179,651,000 in the same period of 2024[73] - Net income for the three months ended September 30, 2025, was $7,658,000, a 59% decrease from $18,719,000 in the same period of 2024[86] - Total revenue for the nine months ended September 30, 2025, was $539.3 million, a slight increase of $0.6 million or 0% compared to $538.7 million in 2024[100] - Operating income rose to $38.5 million, an increase of $4.8 million or 14% compared to $33.7 million in 2024[100] - Net income decreased significantly to $12.7 million, down $18.2 million or 59% from $30.9 million in 2024[100] Visitor and Customer Metrics - Average Monthly Unique Visitors increased by 4% to 25,454,000 for the three months ended September 30, 2025, compared to 24,547,000 in 2024[74] - Dealer Customers increased by 1% to 19,526 for the three months ended September 30, 2025, compared to 19,255 in 2024[74] Revenue Breakdown - Dealer revenue accounted for 89% of total revenue, decreasing by $1.5 million or 0% due to a lower average dealer count and changes in customer mix[100] - OEM and National revenue increased by $0.9 million or 2%, representing 9% of total revenue, driven by increased OEM spending[101] - Other revenue grew by $1.2 million or 13%, maintaining a 2% share of total revenue[101] Expenses - Cost of revenue and operations decreased by 5% to $30,063,000 for the three months ended September 30, 2025, compared to $31,610,000 in 2024[89] - Marketing and sales expenses increased by 2% to $59,336,000 for the three months ended September 30, 2025, compared to $58,288,000 in 2024[92] - General and administrative expenses increased by 13% to $24,325,000 for the three months ended September 30, 2025, compared to $21,511,000 in 2024[93] - Monthly Average Revenue Per Dealer decreased by 1% to $2,460 for the three months ended September 30, 2025, compared to $2,478 in 2024[74] - Interest expense decreased by 5% to $7,631,000 for the three months ended September 30, 2025, compared to $8,028,000 in 2024[95] Share Repurchase and Debt - The company repurchased 5.2 million shares for $63.9 million at an average price of $12.39 per share during the nine months ended September 30, 2025[117] - The company repurchased a total of 1,493,127 shares during the three months ended September 30, 2025, with an average price per share of $12.76 in July, $12.69 in August, and $13.23 in September[138] - The Board of Directors authorized a three-year share repurchase program to acquire up to $250.0 million of the company's common stock[138] - As of September 30, 2025, the maximum dollar value of shares that may yet be purchased under the repurchase program is $195,869,000[138] - The outstanding aggregate principal amount of indebtedness was $455.0 million, with an average interest rate of 6.3%[115] Cash and Liquidity - Cash and cash equivalents as of September 30, 2025, were $55.1 million, with total liquidity of $350.1 million including an undrawn Revolving Loan[114] Internal Controls and Risk Factors - There were no changes in internal control over financial reporting that materially affected the company's financial reporting during the period covered by the report[132] - The company's disclosure controls and procedures were evaluated and deemed effective by the Chief Executive Officer and Chief Financial Officer[130] - There have been no material changes in risk factors affecting the company since the last annual report[136] - The company continues to monitor market risks, with no material changes since December 31, 2024[129] Other Financial Activities - An investment of $8.0 million was made in a secured convertible note for a new customer relationship management platform, maturing in five years[126] - The Chief Financial Officer adopted a trading plan to sell a maximum of 14,818 shares of the company's common stock for tax withholdings[142] - The company reported no unregistered sales of equity securities during the period[137] - The company has not experienced any defaults upon senior securities[140]

Exhibit 99.1 HireQuest Reports Financial Results for Third Quarter 2025 GOOSE CREEK, South Carolina – November 6, 2025 – HireQuest, Inc. (Nasdaq: HQI), a national franchisor of on-demand staffing and executive search services, today reported financial results for the third quarter ended September 30, 2025. Rick Hermanns, HireQuest's President and Chief Executive Officer, commented, "The U.S. staffing industry continued to contend with a muted hiring landscape in the third quarter, as employers maintained a ...

Financial Performance - For the first nine months of 2025, SIGA generated $86 million in product revenues and $33 million in pre-tax operating income[3]. - Product sales for the three months ended September 30, 2025, were $0.9 million, compared to $8.9 million for the same period in 2024, while total revenues were $2.6 million compared to $10.0 million in 2024[4]. - For the nine months ended September 30, 2025, product sales reached $85.8 million, up from $53.5 million in 2024, with total revenues increasing to $90.8 million from $57.3 million[4]. - The net income for the nine months ended September 30, 2025, was $28.7 million, compared to $13.5 million in 2024, resulting in a diluted income per share of $0.40 versus $0.19[4]. - Total revenues for the three months ended September 30, 2025, were $2,620,000, a decrease from $10,009,781 in the same period of 2024[17]. - Product sales and supportive services generated $889,748 in Q3 2025, compared to $8,942,875 in Q3 2024, reflecting a significant decline[17]. - The company reported a net income of $28,709,061 for the nine months ended September 30, 2025, compared to $13,453,901 in the same period of 2024[17]. Funding and Development - The company received $13 million in funding for the TPOXX pediatric development program under the BARDA 19C contract, in addition to $14 million for manufacturing activities, totaling $27 million in development funding added during Q2 2025[11]. - SIGA delivered $53 million of oral TPOXX revenues and $26 million of IV TPOXX revenues to the U.S. Strategic National Stockpile in the first nine months of 2025[11]. - A procurement order for $26 million of IV TPOXX was received from the U.S. Government under the BARDA contract in March 2025[11]. Cash and Assets - As of September 30, 2025, SIGA's cash and cash equivalents totaled approximately $172 million, an increase from $155 million as of December 31, 2024[16]. - Total assets decreased to $231.6 million as of September 30, 2025, from $244.3 million as of December 31, 2024[16]. Dividends and Shareholder Returns - The company declared a special cash dividend of $0.60 per share on April 8, 2025, which was paid on May 15, 2025[7]. Operating Expenses and Losses - Research and development expenses increased to $7,053,985 in Q3 2025, up from $3,024,593 in Q3 2024, indicating a 133% rise[17]. - Operating loss for the three months ended September 30, 2025, was $(10,222,579), compared to an operating income of $542,087 in the same period of 2024[17]. - Net and comprehensive loss for Q3 2025 was $(6,365,819), contrasting with a net income of $1,343,945 in Q3 2024[17]. - Basic loss per share for Q3 2025 was $(0.09), compared to a basic income per share of $0.02 in Q3 2024[17]. - Total operating expenses for the nine months ended September 30, 2025, were $57,578,927, up from $44,353,199 in the same period of 2024[17]. Shares Outstanding - Weighted average shares outstanding for basic shares increased slightly to 71,604,956 in Q3 2025 from 71,368,585 in Q3 2024[17]. Other Income - Other income for the three months ended September 30, 2025, was $1,866,693, compared to $1,330,505 in Q3 2024, showing an increase of 40%[17].

Financial Performance - GAAP net sales for Q3 2025 were $90.6 million, a decrease of 11.5% from $102.1 million in Q3 2024[7] - GAAP net sales in connected home increased to $29.8 million, up 12.9% from $26.4 million in Q3 2024[7] - GAAP net sales in home entertainment decreased to $60.8 million, down 19.7% from $75.7 million in Q3 2024[7] - Net sales for Q3 2025 were $90,552 thousand, a decrease of 11.8% from $102,073 thousand in Q3 2024[21] - Gross profit for Q3 2025 was $25,122 thousand, down 18.4% from $30,732 thousand in Q3 2024[21] - Operating loss for Q3 2025 was $(4,512) thousand compared to an operating income of $418 thousand in Q3 2024[21] - For the three months ended September 30, 2025, the GAAP net loss was $8.329 million, compared to a net loss of $2.658 million for the same period in 2024[29] - Adjusted non-GAAP net income for the three months ended September 30, 2025, was $1.110 million, a decrease from $1.361 million in 2024[29] - The diluted earnings per share (GAAP) for the three months ended September 30, 2025, was $(0.62), compared to $(0.20) in 2024[29] Future Projections - The company expects Q4 2025 GAAP net sales to range from $82.0 million to $92.0 million, down from $110.5 million in Q4 2024[6] - The company expects net sales for the fourth quarter of 2025 to range from $82 million to $92 million, with connected home sales projected between $26 million and $30 million[32] - GAAP loss per share for Q4 2025 is expected to range from $0.30 to $0.20, an improvement from a loss of $0.35 in Q4 2024[7] - The adjusted non-GAAP diluted earnings per share for the fourth quarter of 2025 is projected to be between $0.01 and $0.11[32] Cash Flow and Liquidity - Operating cash flows generated in Q3 2025 were $10.1 million, compared to $5.7 million in Q3 2024[7] - Cash and cash equivalents as of September 30, 2025, were $31.5 million, up from $26.8 million at the end of 2024[19] - Cash flows from operating activities for the nine months ended September 30, 2025, were $27,837 thousand, significantly higher than $8,339 thousand in the same period of 2024[23] - Cash and cash equivalents at the end of the period were $31,506 thousand, an increase from $26,287 thousand at the end of the same period in 2024[23] Expenses and Charges - Research and development expenses for Q3 2025 were $6,687 thousand, a decrease of 8.9% from $7,338 thousand in Q3 2024[21] - The company incurred impairment charges of $1.187 million related to machinery and equipment due to the shutdown of its Mexico manufacturing facility, expected to be completed by the end of 2025[29] - Severance costs associated with a global reduction in force amounted to $1.705 million for the three months ended September 30, 2025[29] Shareholder Actions - The board authorized a share repurchase of up to $3.5 million or approximately 778,000 shares[3] Segment Performance - The connected home segment generated $29,793 thousand in sales for Q3 2025, up 12.8% from $26,368 thousand in Q3 2024[25] - The home entertainment segment saw sales decline to $60,759 thousand in Q3 2025 from $75,705 thousand in Q3 2024, a decrease of 19.8%[25] Adjusted Metrics - Adjusted non-GAAP operating income for Q3 2025 was $1,570 thousand, compared to $2,567 thousand in Q3 2024[27] - Total adjustments for the diluted earnings per share in the fourth quarter of 2025 are estimated at $0.31[32] - The company reported a foreign currency gain of $1.109 million for the three months ended September 30, 2025[29] - The total diluted shares used in computing earnings per share (GAAP) for the three months ended September 30, 2025, was 13,340 thousand shares[29]

Exhibit 99.1 Texas Roadhouse, Inc. Announces Third Quarter 2025 Results Declares Quarterly Dividend of $0.68 per Share LOUISVILLE, KY. (November 6, 2025) – Texas Roadhouse, Inc. (NasdaqGS: TXRH), today announced financial results for the 13 and 39 weeks ended September 30, 2025. Financial Results Financial results for the 13 and 39 weeks ended September 30, 2025 and September 24, 2024 were as follows: | | 13 Weeks Ended | | | 39 Weeks Ended | | | | --- | --- | --- | --- | --- | --- | --- | | ($000's, except ...